|
1
|
Kim N, He N, Kim C, Zhang F, Lu Y, Yu Q,
Stemke-Hale K, Greshock J, Wooster R, Yoon S, et al: Systematic
analysis of genotype-specific drug responses in cancer. Int J
Cancer. 131:2456–2464. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Settleman J: Cell culture modeling of
genotype-directed sensitivity to selective kinase inhibitors:
Targeting the anaplastic lymphoma kinase (ALK). Semin Oncol.
36(Suppl 1): S36–S41. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
He N, Kim N, Song M, Park C, Kim S, Park
EY, Yim HY, Kim K, Park JH, Kim KI, et al: Integrated analysis of
transcriptomes of cancer cell lines and patient samples reveals
STK11/LKB1-driven regulation of cAMP phosphodiesterase-4D. Mol
Cancer Ther. 13:2463–2473. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Knudsen ES and Knudsen KE: Tailoring to
RB: Tumour suppressor status and therapeutic response. Nat Rev
Cancer. 8:714–724. 2008. View
Article : Google Scholar
|
|
5
|
Xie Z and Liu D: Pathogenesis of molecular
signaling pathways changes in smoking-induced lung cancer. Zhongguo
Fei Ai Za Zhi. 12:1202–1205. 2009.in Chinese.
|
|
6
|
Serrano M, Hannon GJ and Beach D: A new
regulatory motif in cell-cycle control causing specific inhibition
of cyclin D/CDK4. Nature. 366:704–707. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Hernando E, Nahlé Z, Juan G,
Diaz-Rodriguez E, Alaminos M, Hemann M, Michel L, Mittal V, Gerald
W, Benezra R, et al: Rb inactivation promotes genomic instability
by uncoupling cell cycle progression from mitotic control. Nature.
430:797–802. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Dyson N: The regulation of E2F by
pRB-family proteins. Genes Dev. 12:2245–2262. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Classon M and Harlow E: The retinoblastoma
tumour suppressor in development and cancer. Nat Rev Cancer.
2:910–917. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kosaka T, Yatabe Y, Endoh H, Kuwano H,
Takahashi T and Mitsudomi T: Mutations of the epidermal growth
factor receptor gene in lung cancer: Biological and clinical
implications. Cancer Res. 64:8919–8923. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Shigematsu H, Lin L, Takahashi T, Nomura
M, Suzuki M, Wistuba II, Fong KM, Lee H, Toyooka S, Shimizu N, et
al: Clinical and biological features associated with epidermal
growth factor receptor gene mutations in lung cancers. J Natl
Cancer Inst. 97:339–346. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Singh B, Reddy PG, Goberdhan A, Walsh C,
Dao S, Ngai I, Chou TC, O-Charoenrat P, Levine AJ, Rao PH, et al:
p53 regulates cell survival by inhibiting PIK3CA in squamous cell
carcinomas. Genes Dev. 16:984–993. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Blanco R, Iwakawa R, Tang M, Kohno T,
Angulo B, Pio R, Montuenga LM, Minna JD, Yokota J and
Sanchez-Cespedes M: A gene-alteration profile of human lung cancer
cell lines. Hum Mutat. 30:1199–1206. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Etemadmoghadam D, Weir BA, Au-Yeung G,
Alsop K, Mitchell G, George J, Davis S, D'Andrea AD, Simpson K,
Hahn WC, et al; Australian Ovarian Cancer Study Group. Synthetic
lethality between CCNE1 amplification and loss of BRCA1. Proc Natl
Acad Sci USA. 110:19489–19494. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Shoemaker RH, Monks A, Alley MC, Scudiero
DA, Fine DL, McLemore TL, Abbott BJ, Paull KD, Mayo JG and Boyd MR:
Development of human tumor cell line panels for use in
disease-oriented drug screening. Prog Clin Biol Res. 276:265–286.
1988.PubMed/NCBI
|
|
16
|
Greshock J, Bachman KE, Degenhardt YY,
Jing J, Wen YH, Eastman S, McNeil E, Moy C, Wegrzyn R, Auger K, et
al: Molecular target class is predictive of in vitro response
profile. Cancer Res. 70:3677–3686. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Forbes SA, Bindal N, Bamford S, Cole C,
Kok CY, Beare D, Jia M, Shepherd R, Leung K, Menzies A, et al:
COSMIC: mining complete cancer genomes in the Catalogue of Somatic
Mutations in Cancer. Nucleic Acids Res. 39(Database): D945–D950.
2011. View Article : Google Scholar :
|
|
18
|
Kim N, He N and Yoon S: Cell line modeling
for systems medicine in cancers (Review). Int J Oncol. 44:371–376.
2014.
|
|
19
|
Jeong E, He N, Park H, Song M, Kim N, Lee
S and Yoon S: MACE: mutation-oriented profiling of chemical
response and gene expression in cancers. Bioinformatics.
31:1508–1514. 2015. View Article : Google Scholar
|
|
20
|
McDermott U, Sharma SV, Dowell L,
Greninger P, Montagut C, Lamb J, Archibald H, Raudales R, Tam A,
Lee D, et al: Identification of genotype-correlated sensitivity to
selective kinase inhibitors by using high-throughput tumor cell
line profiling. Proc Natl Acad Sci USA. 104:19936–19941. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Vasudevan KM, Barbie DA, Davies MA,
Rabinovsky R, McNear CJ, Kim JJ, Hennessy BT, Tseng H, Pochanard P,
Kim SY, et al: AKT-independent signaling downstream of oncogenic
PIK3CA mutations in human cancer. Cancer Cell. 16:21–32. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Craft CS, Zou W, Watkins M, Grimston S,
Brodt MD, Broekelmann TJ, Weinbaum JS, Teitelbaum SL, Pierce RA,
Civitelli R, et al: Microfibril-associated glycoprotein-1, an
extra-cellular matrix regulator of bone remodeling. J Biol Chem.
285:23858–23867. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Stemke-Hale K, Gonzalez-Angulo AM, Lluch
A, Neve RM, Kuo WL, Davies M, Carey M, Hu Z, Guan Y, Sahin A, et
al: An integrative genomic and proteomic analysis of PIK3CA, PTEN,
and AKT mutations in breast cancer. Cancer Res. 68:6084–6091. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Tibes R, Qiu Y, Lu Y, Hennessy B, Andreeff
M, Mills GB and Kornblau SM: Reverse phase protein array:
validation of a novel proteomic technology and utility for analysis
of primary leukemia specimens and hematopoietic stem cells. Mol
Cancer Ther. 5:2512–2521. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Agresti A; John Wiley & Sons.
Categorical Data Analysis. Wiley Series in Probability and
Statistics. Wiley-Interscience; New York: 2002
|
|
26
|
Kim N, Park H, He N, Lee HY and Yoon S:
QCanvas: An Advanced Tool for Data Clustering and Visualization of
Genomics Data. Genomics Inform. 10:263–265. 2012. View Article : Google Scholar
|
|
27
|
Subramanian A, Tamayo P, Mootha VK,
Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub
TR, Lander ES, et al: Gene set enrichment analysis: a
knowledge-based approach for interpreting genome-wide expression
profiles. Proc Natl Acad Sci USA. 102:15545–15550. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Rocco JW and Sidransky D:
p16(MTS-1/CDKN2/INK4a) in cancer progression. Exp Cell Res.
264:42–55. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Gilkes DM, Semenza GL and Wirtz D: Hypoxia
and the extra-cellular matrix: drivers of tumour metastasis. Nat
Rev Cancer. 14:430–439. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Mazieres J, He B, You L, Xu Z and Jablons
DM: Wnt signaling in lung cancer. Cancer Lett. 222:1–10. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Chang F, Steelman LS, Lee JT, Shelton JG,
Navolanic PM, Blalock WL, Franklin RA and McCubrey JA: Signal
transduction mediated by the Ras/Raf/MEK/ERK pathway from cytokine
receptors to transcription factors: potential targeting for
therapeutic intervention. Leukemia. 17:1263–1293. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Wang S and Basson MD: Akt directly
regulates focal adhesion kinase through association and serine
phosphorylation: Implication for pressure-induced colon cancer
metastasis. Am J Physiol Cell Physiol. 300:C657–C670. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Song MS, Salmena L and Pandolfi PP: The
functions and regulation of the PTEN tumour suppressor. Nat Rev Mol
Cell Biol. 13:283–296. 2012.PubMed/NCBI
|
